Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EUDA Health Holdings (EUDA) Cash & Equivalents (2021 - 2025)

EUDA Health Holdings (EUDA) has disclosed Cash & Equivalents for 4 consecutive years, with $200000.0 as the latest value for Q4 2024.

  • Quarterly Cash & Equivalents rose 1.24% to $200000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2024, up 1.24% year-over-year, with the annual reading at $200000.0 for FY2024, 1.24% up from the prior year.
  • Cash & Equivalents for Q4 2024 was $200000.0 at EUDA Health Holdings, up from $197554.0 in the prior quarter.
  • The five-year high for Cash & Equivalents was $837292.0 in Q1 2023, with the low at $189996.0 in Q4 2021.
  • Average Cash & Equivalents over 4 years is $441865.4, with a median of $200000.0 recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 312.9% in 2022, then crashed 74.82% in 2023.
  • Over 4 years, Cash & Equivalents stood at $189996.0 in 2021, then skyrocketed by 312.9% to $784485.0 in 2022, then plummeted by 74.82% to $197554.0 in 2023, then increased by 1.24% to $200000.0 in 2024.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $200000.0, $197554.0, and $837292.0 for Q4 2024, Q4 2023, and Q1 2023 respectively.